CeriBell EEG (CBLL): Price-to-Revenue Ratio

Corporate company logo of CeriBell Inc (CBLL)

CeriBell, Inc. maintains sufficient liquidity by leveraging operational cash flow from the implementation of neural networks. High pricing power within intensive care units is driven by the critical nature of rapid seizure diagnostics. The estimated P/S ratio reflects the dynamics of this demand, where 9.40 determines the current value of the metric. The growth in capitalization for CeriBell, Inc. is stimulated by the expansion of insurance coverage, sales of consumables, and the expansion of AI brain monitoring across US clinics.

CBLL: CeriBell P/S Multiple 08/07/2025 - 11/13/2026

Analytical breakdowns for CeriBell Corp (CBLL)

- current price and projected stock value:
Price Chart ceribell.com|CBLL - Price Target Chart
- stock exchange capitalization data:
Market Value CeriBell Corp|CBLL - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value of a Share CeriBell|CBLL - Book Capitalization|Market Capitalization to Book Value ceribell.com|CBLL - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Ratio CeriBell, Inc.|CBLL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio CeriBell EEG|CBLL - Company Total Debt|Debts to Net Assets CeriBell Corp|CBLL - Company Long-Term Debts|Company Current Liabilities CeriBell|Quick Liquidity ceribell.com
- earnings and valuation multiples information:
CBLL - Company Net Income|Expected Profit CeriBell, Inc.|CBLL - Price to Earnings Ratio|Future Price to Earnings CeriBell Inc|CBLL - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation CeriBell Corp|CBLL - Operating profit EBITDA|Net earnings per one share for the last twelve months CeriBell|CBLL - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ceribell.com|CBLL - Earnings per share growth in current year|Expected earnings per share trend next year CeriBell, Inc.
- issuer revenue and sales details:
CBLL - Company Revenue|Company Expected Sales Volume ceribell.com|CBLL - P/S Multiple|Forward Price-to-Revenue Multiple CeriBell Corp
Summary company analytics:CBLL, ceribell.com
Manufactured products of CeriBell, Inc.

To assess the financial stability of CeriBell, Inc. (CBLL), it is essential to compare the business's market value with its actual cash flow from AI brain diagnostics. By analyzing the company's P/S ratio, which stands at 9.40, an investor can see the ratio of market capitalization to annual revenue, making it possible to determine the degree of stock overvaluation relative to the adoption rate of innovative EEG headbands in intensive care units and overall sales scaling.

Competing companies

Price-to-Revenue Ratio BIIB (biogen.com)|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd - Price-to-Revenue Ratio|AXSM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|XENE: P/S Multiple|VKTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Supernus|Market Cap to Revenue Ratio CPRX (Catalyst Pharma)|P/S Multiple DNLI|Market Cap to Revenue Harmony Corp HRMY|Biohaven Ltd. - Market Cap to Revenue|Price-to-Revenue Coefficient amylyx.com (AMLX)|Trevi Therapeutics, Inc. - P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Market Cap to Revenue|AVXL: P/S Multiple|PRTA (Prothena Corp) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Alector Inc.|Price-to-Revenue Ratio ANNX|Price-to-Revenue Ratio Omeros Corporation (OMER)|Price-to-Revenue Ratio NGNE (Neurogene Inc)|Price-to-Revenue Ratio AC Immune Corp ACIU|VYGR: Market Cap to Revenue Ratio|Neumora Therapeutics - P/S Multiple|Price to Sales scilexholding.com|TVGN (Tevogen Bio) - Market Cap to Revenue|Alpha Cognition Inc. (ACOG) - P/S Multiple|Price-to-Revenue Ratio Cognition Therapeutics, Inc.|IKT: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cassava Sciences, Inc. (SAVA)|ASRT - Price to Sales|P/S Multiple COYA (Coya Therapeutics)|VTGN - Market Cap to Revenue|Ovid Rx - P/S Multiple|Price to Sales Acumen Pharmaceuticals, Inc|CervoMed Inc. (CRVO) - Price-to-Revenue Ratio|Alterity Therapeutics Limited - Market Capitalization-to-Revenue Ratio|CLNN (Clene Inc) - P/S Multiple|PepGen Corp (PEPG) - Price-to-Revenue Coefficient|P/S Multiple JUNS|Price-to-Revenue Ratio RLMD (Relmada Corp)|P/S Multiple ANVS (Annovis Bio, Inc.)|Grace Therapeutics Inc (GRCE) - Price to Sales|AIFF - Price-to-Revenue Ratio|KLTO: Price-to-Revenue Ratio|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|RVPH (Reviva Pharmaceuticals, Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue MTVA|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|Price-to-Revenue Coefficient passagebio.com|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|NERV: Market Cap to Revenue Ratio|Athira Pharma, Inc. - P/S Multiple|addextherapeutics.com (ADXN) - Market Cap to Revenue|ALZN (alzamend.com) - Market Cap to Revenue|CYCN - Price-to-Revenue Coefficient|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|Market Cap to Revenue Pasithea (KTTA)|P/S Multiple CRGT|Price-to-Revenue Ratio ATXI (avenuetx.com)|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. - Price-to-Revenue Ratio|CHRO - Price-to-Revenue Ratio|ELYM: Price-to-Revenue Ratio|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Price to Sales NKGen Biotech Inc NKGN|Market Cap to Revenue NRBO (NeuroBo)|P/S Multiple Sage Therapeutics Inc (SAGE)|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|Market Capitalization-to-Revenue Ratio TRVN|VIGL - Price-to-Revenue Ratio|Price to Sales anewmeds.com|CERE: P/S Multiple